Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Lyophilized formulation specific testing is a dedicated service for the drug product release of freeze‑dried injectables. It systematically quantifies residual moisture, reconstitution time, and lyophilized cake appearance, with methods designed to align with USP requirements to ensure stability during storage, usability after reconstitution, and clinical safety.
Freeze drying converts liquid drugs into stable solid cakes by sublimation, extending shelf life for thermosensitive products such as biologics, vaccines, antibodies, and peptides. Three critical quality attributes are covered by this service.
Residual moisture catalyzes hydrolysis, deamidation, and oxidation, leading to potency loss, aggregation, and appearance changes. Typical residual moisture for lyophilized biologics is 0.5–3.0% w/w. Karl Fischer titration is the gold standard, based on the quantitative reaction of water with sulfur dioxide and iodine.
The time required for the lyophilized cake to fully dissolve in the specified diluent (water for injection, saline, or product‑specific buffer) under defined conditions (room temperature, gentle swirling, or static). Short reconstitution time is critical for clinical convenience, especially in emergency settings. Prolonged time may indicate a dense cake, over‑drying, or physical changes during storage.
Cake appearance directly reflects process adequacy and batch consistency. An ideal cake is white to off‑white, porous, intact, with a smooth surface and no collapse, cracks, shrinkage, or foreign matter. Regulatory authorities mandate 100% visual inspection for key defects such as cracks, meltback, and particulates.
| Document | Section | Key Requirement |
| USP <921> | Water Determination | Standard for KF titration: volumetric (Method Ia) and coulometric (Method Ic). |
| USP <922> | Water Activity | Effective May 2021; complementary to total moisture. |
| USP <790> | Visible Particulates | Applicable to the reconstituted solution and cake appearance. |
| USP <1> | Injections | Reconstitution requirements for lyophilized injectables. |
| ICH Q1A(R2) | Stability Testing | Moisture is a critical factor for lyophilized products. |
| ICH Q5C | Stability of Biotech Products | Post‑reconstitution stability must be demonstrated. |
| ICH Q9 | Quality Risk Management | Risk‑based approach for cake appearance assessment. |
| Ph. Eur. 2.5.12 | Water Determination | Harmonized with USP <921>. |
| WHO TRS 1010 | Vaccine Stability | Recommends assessing cake structure and moisture. |
Q1: What is the typical acceptance criterion for residual moisture in lyophilized formulations?
A: Residual moisture is typically controlled between 0.5% and 3.0% w/w, depending on the product. In practice, lyophilized biologics often require ≤1.5%, and some products require ≤1.0%. Water activity (Aw) is typically ≤0.60 to ensure stability. The final criterion must be scientifically justified based on product characteristics, target shelf life, and storage conditions, and documented in regulatory filings.
Q2: How should samples be handled for moisture testing of lyophilized formulations?
A: Avoid moisture uptake during handling. Recommended practices: operate in a low‑humidity environment (glove box, RH <20%); take representative samples (at least 2‑5 vials combined); sample whole vial without grinding (or crush under dry conditions to increase methanol contact); weigh quickly and titrate immediately; run a solvent blank; record ambient temperature and humidity. Sample size must meet method sensitivity (volumetric: 0.1‑1 g, coulometric: 10‑100 mg).
Copyright © 2026 Creative Biogene. All rights reserved.